Mignane Ka

Mignane Ka

Auto-generated profile, based on publicly available information

Mignane Ka

Department of Medicine and Division of Hematology/Oncology and

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
JFJulien Fourcade
Julien Fourcade
ZSZhaojun Sun
Zhaojun Sun
JCJoe-Marc Chauvin
Joe-Marc Chauvin
MKMignane Ka
Mignane Ka
DDDiwakar Davar
Diwakar Davar
HZHassane M. Zarour
Hassane M. Zarour
CD4 + Tregs impede T cell responses to tumors. They express multiple inhibitory receptors that support their suppressive functions, including T cell Ig and ITIM domain (TIGIT). In melanoma patients, we show that Tregs exhibit increased TIGIT expression and decreased expression of its competing costimulatory receptor CD226 as compared with CD4 + effector T cells, resulting in an increased TIGIT/CD226 ratio. Tregs failed to upregulate CD226 upon T cell activation. TIGIT + Tregs are highly suppressive, stable, and enriched in tumors. TIGIT and CD226 oppose each other to augment or disrupt, respectively, Treg suppression and stability. A high TIGIT/CD226 ratio in Tregs correlates with increased Treg frequencies in tumors and poor clinical outcome upon immune checkpoint blockade. Altogether, our findings show that a high TIGIT/CD226 ratio in Tregs regulates their suppressive function and stability in melanoma. They provide the rationale for novel immunotherapies to activate CD226 in Tregs together with TIGIT blockade to counteract Treg suppression in cancer patients.